GlassScriptPhysician profile
Laura C Bunch
NPI 1295773125
$10,124.79
in general payments reported to CMS, 2019-2025
68 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $585 · 2021: $735 · 2022: $1,856 · 2023: $2,229 · 2024: $2,002 · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,327 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,326.77 |
| Education | $272.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,050.06 | 2020-2025 | Imfinzi, Lynparza, Calquence |
| Novartis Pharmaceuticals Corporation | $840.18 | 2019-2025 | |
| Daiichi Sankyo INC. | $812.74 | 2019-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $589.81 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $561.32 | 2019-2025 | Opdivo, Opdualag |
| Myriad Genetic Laboratories, INC. | $418.35 | 2019-2023 | Myrisk, Bracanalysis Cdx, Precisetumor |
| Merck Sharp & Dohme LLC | $394.39 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Stemline Therapeutics INC. | $345.02 | 2022-2025 | Orserdu |
| Abbvie INC. | $294.64 | 2021-2025 | Venclexta |
| Pfizer INC. | $254.63 | 2019-2025 | |
| Seagen INC. | $226.93 | 2021-2025 | Tukysa |
| Eisai INC. | $223.14 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $219.38 | 2020-2023 | Imbruvica, Epkinly |
| Amgen INC. | $209.98 | 2020-2023 | Lumakras, Kyprolis |
| Celgene Corporation | $193.84 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $182.32 | 2023-2024 | Besremi |
| Ipsen Biopharmaceuticals, INC | $178.26 | 2022-2025 | Onivyde, Somatuline Depot |
| Incyte Corporation | $175.87 | 2020-2025 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $175.73 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.70 | 2022-2025 | Ninlaro, Fruzaqla |
| Astellas Pharma US INC | $135.51 | 2022-2025 | Xtandi |
| Genentech USA, INC. | $134.66 | 2021-2025 | Tecentriq, Columvi, Lunsumio |
| Morphosys, US INC. | $133.05 | 2021-2024 | Monjuvi |
| Genzyme Corporation | $130.64 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $130.55 | 2022-2024 | Fotivda |
| Foundation Medicine, INC. | $114.92 | 2021-2023 | |
| Gilead Sciences, INC. | $113.99 | 2021-2024 | Trodelvy |
| Sobi, INC | $108.26 | 2022-2023 | |
| Array Biopharma INC | $106.79 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.58 | 2021-2023 | Gilotrif |
| Exelixis INC. | $87.20 | 2019-2025 | Cabometyx |
| Beone Medicines USA, INC. | $81.68 | 2025 | Brukinsa, Tevimbra |
| Lilly USA, LLC | $73.83 | 2019-2022 | |
| Glaxosmithkline, LLC. | $60.59 | 2021-2023 | Shingrix, Ojjaara |
| Acrotech Biopharma INC. | $53.68 | 2022-2023 | Beleodaq |
| Puma Biotechnology, INC. | $52.64 | 2024-2025 | |
| Beigene USA, INC. | $50.75 | 2022-2025 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $49.31 | 2022 | |
| Adc Therapeutics America, INC. | $48.94 | 2022-2023 | |
| Pharmacosmos Therapeutics INC. | $47.43 | 2022-2025 | Monoferric |
| Global Blood Therapeutics, INC. | $46.88 | 2022 | |
| Rigel Pharmaceuticals, INC. | $46.45 | 2022-2023 | Rezlidhia, Tavalisse |
| Immunocore Limited | $43.66 | 2025 | Kimmtrak |
| Fennec Pharmaceuticals, INC. | $40.67 | 2025 | Fyarro |
| Regeneron Healthcare Solutions, INC. | $40.66 | 2023 | Libtayo |
| Deciphera Pharmaceuticals INC. | $40.55 | 2022-2024 | Qinlock |
| Genmab U.S., INC. | $40.35 | 2023 | Epkinly |
| Blueprint Medicines Corporation | $39.53 | 2022-2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $38.35 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $37.42 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $35.25 | 2025 | Orgovyx |
| Emd Serono, INC. | $32.19 | 2024-2025 | |
| Taiho Oncology, INC. | $30.69 | 2020-2022 | |
| Adaptive Biotechnologies Corporation | $28.11 | 2023 | Clonoseq |
| Recordati_rare_diseases_inc. | $23.89 | 2025 | Sylvant |
| Kite Pharma, INC. | $21.06 | 2025 | Yescarta |
| Agios Pharmaceuticals, INC. | $20.80 | 2025 | Pyrukynd |
| Novocure INC. | $20.37 | 2025 | Optune Lua (Novottf-200t) |
| G1 Therapeutics, INC. | $18.54 | 2023 | Cosela |
| Dova Pharmaceuticals | $18.21 | 2020 | |
| Servier Pharmaceuticals LLC | $16.73 | 2022 | |
| Mirati Therapeutics, INC. | $16.62 | 2023 | Krazati |
| Epizyme, INC. | $15.63 | 2022 | |
| Coherus Oncology, INC. | $15.11 | 2023 | |
| Macrogenics, INC. | $14.10 | 2022 | |
| Karyopharm Therapeutics INC. | $14.02 | 2023 | Xpovio |
| Secura Bio, INC. | $13.89 | 2021 | |
| Myovant Sciences INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Bunch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.